Table 1.
Patient Population Baseline Characteristics in the 2 Data Sets
| Characteristics | Data set 1 (N = 2593) | Data set 2 (N = 626) |
|---|---|---|
| Age, mean ± SD [median] | 73.3 ± 10.4 [75.0] | 68.4 ± 10.6 [66.0] |
| Age group, N (%) | ||
| <55 yrs | 102 (3.9) | 46 (7.3) |
| 55–64 yrs | 557 (21.5) | 238 (38.0) |
| 65–74 yrs | 607 (23.4) | 158 (25.2) |
| ≥75 yrs | 1327 (51.2) | 184 (29.4) |
| Payer type, N (%) | ||
| Medicare enrollees | 1898 (73.2) | 2 (0.3) |
| Commercial claims enrollees | 695 (26.8) | 623 (99.5) |
| HMO | 70 (2.7) | 63 (10.1) |
| PPO | 440 (17.0) | 75 (12.0) |
| POS | 84 (3.2) | 310 (49.5) |
| Indemnity | 0 (0.0) | 135 (21.6) |
| EPO | 0 (0.0) | 38 (6.1) |
| Other/unknown | 101 (3.9) | 2 (0.3) |
| Medicaid enrollees | 0 (0.0) | 1 (0.2) |
| Region, N (%) | ||
| Midwest | 988 (38.1) | 198 (31.6) |
| Northeast | 263 (10.1) | 40 (6.4) |
| South | 848 (32.7) | 265 (42.3) |
| West | 491 (18.9) | 123 (19.6) |
| Unknown | 3 (0.1) | 0 (0.0) |
| Year of index date, N (%) | ||
| 2005 | 369 (14.2) | 5 (0.8) |
| 2006 | 475 (18.3) | 93 (14.9) |
| 2007 | 565 (21.8) | 103 (16.5) |
| 2008 | 547 (21.1) | 110 (17.6) |
| 2009 | 504 (19.4) | 100 (16.0) |
| 2010 | 133 (5.1) | 89 (14.2) |
| 2011 | 0 (0.0) | 104 (16.6) |
| 2012 | 0 (0.0) | 22 (3.5) |
| Clinical history, N (%) | ||
| Charlson comorbidity index, mean ± SD [median] | 0.8 ± 1 [0.0] | 1.0 ± 1.4 [1.0] |
| Diabetes | 516 (19.9) | 150 (24.0) |
| Hypertension | 907 (35.0) | 336 (53.7) |
| Cardiovascular diseases | 892 (34.4) | 199 (31.8) |
| Seizures | 21 (0.8) | 10 (1.6) |
| Metastatic sites at first metastatic diagnosis, N (%) | ||
| Secondary and unspecified malignant neoplasm of lymph nodes | 240 (9.3) | 68 (10.9) |
| Secondary malignant neoplasm of respiratory and digestive systems | 167 (6.4) | 39 (6.2) |
| Secondary malignant neoplasm of other specified sites | 1955 (75.4) | 461 (73.6) |
| Kidney | 1 (0.0) | 0 (0.0) |
| Other urinary organs | 63 (2.4) | 15 (2.4) |
| Skin | 3 (0.1) | 0 (0.0) |
| Brain and spinal cord | 45 (1.7) | 5 (0.8) |
| Other parts of nervous system | 2 (0.1) | 0 (0.0) |
| Bone and bone marrow | 1630 (62.9) | 400 (63.9) |
| Adrenal gland | 3 (0.1) | 1 (0.2) |
| Other specified sites | 208 (8.0) | 40 (6.4) |
| Malignant neoplasm without specification of site | 231 (8.9) | 58 (9.3) |
| Observation period, mean days ± SD [median] | 493.3 ± 409.1 [403.0] | 478.0 ± 434.3 [347.0] |
EPO indicates exclusive provider organization; HMO, health maintenance organization; POS, point of service; PPO, preferred provider organization; SD, standard deviation.